TRPV1 and Parkinson disease: A recent study has shown that Cu2-x-Se-anti-TRPV1 nanoparticles can target the microglia and open a TRPV1 channel on its surface under second near-infrared (NIR-II) laser irradiation, and cause an influx of Ca2+ to activate the autophagy protein 5 (ATG5) and Ca2+/CaMKK2/AMPK/mTOR signaling pathways, which promote the phagocytosis and degradation of α-Syn, and improve treatment for PD [4].